Skip to content
Search resources Open menu

Forensic Topics

ADHD Treatment, Medication, and Offending Risk

Published

Snap Shot

  • The question: Does treating attention-deficit/hyperactivity disorder (ADHD), with medication or psychosocial therapy, lower the risk of offending, including sexual offending, and how should that evidence be used in sentencing, custody, and supervision?
  • What the research shows: Large Swedish, Danish, Norwegian, and Dutch register studies found lower rates of convictions or charges for general crime, most evident for impulsive and reactive offenses, during medicated periods (about 13% to 41% lower in the headline estimates, depending on study, outcome, and sex); the benefit is modest and short-term, and the studies are observational. A U.S. insurance-claims study found fewer substance-related emergency visits during medicated months. Cognitive-behavioral therapy improves adult ADHD symptoms. Stimulant misuse and diversion are real risks that clinical guidance addresses through screening and the choice of medication.
  • What it does not show: No study shows that ADHD medication reduces sexual offending; the one quasi-experimental study that examined sexual charges found no evidence of an effect but could not rule out a small one, and two prison trials disagree on whether methylphenidate reduces symptoms there. Group findings cannot predict how a particular defendant will respond to treatment or whether he will take it.
  • The law: Federal courts may require treatment as a condition of probation or supervised release, but in the Ninth Circuit a condition that implicates a particularly significant liberty interest, such as compelled psychotropic medication, requires specific, medically grounded findings. Since a 2026 amendment (Laws 2026, ch. 186, approved June 19, 2026, general effective date September 12, 2026), Arizona probation conditions must be reasonably necessary, individually determined, and narrowly tailored unless otherwise required by law; whether it applies to offenses committed before its effective date should be checked.
  • Issues for each side: Prosecutors can rely on treatment evidence as a reason for structured supervision while questioning claims that medication alone answers sexual-offense risk; defense counsel can present documented, sustained treatment as a responsivity and mitigation factor without promising that medication will prevent reoffending.

When a defendant in a sex offense case has ADHD, a treatment plan often follows the diagnosis: resume medication, add skills-based therapy, and adapt sex-offender treatment. Attorneys meet this plan at sentencing, in supervision conditions, and in disputes over medication in custody. A widely cited Swedish register study is often offered to show that ADHD medication reduces crime; what it and later studies measured determines how far that evidence reaches.

Two premises frame the paper. First, sexual offenses harm the people victimized, and neither ADHD nor its treatment is a defense; a treatment plan bears on risk management, responsivity, and mitigation, not on whether an offense occurred. Second, the evidence cuts both ways: it supports treating ADHD as a legitimate part of risk management, and it shows that the measured benefits are modest, concern general rather than sexual crime, and depend on continued medication.

ADHD’s association with sexual offending is reviewed in “ADHD and Sexual Offending: What the Research Shows,” and diagnosis after arrest in “Diagnosing ADHD in Adult Defendants: Records, Rating Scales, and Feigning.”

What the Registry Studies Found

The study most often cited linked Swedish national registers for 25,656 people with ADHD from 2006 through 2009 and compared each person’s conviction rate while taking ADHD medication with the same person’s rate while not taking it (Lichtenstein et al., 2012). Conviction rates during medicated periods were 32% lower for men and 41% lower for women. Among men, reductions ranged from 17% to 46% in sensitivity analyses, including for stimulants, nonstimulants, and violent and drug-related convictions. The authors raised the possibility that medication reduces criminality; they did not claim to have proved it.

Later studies used different designs. In a Danish national cohort of 4,231 children with ADHD followed to a mean age of 22, crime rates were lower during periods of medication, and co-occurring substance use disorder strongly increased conviction risk (Mohr-Jensen et al., 2019). In Dutch records for 18,234 adolescents, high-adherence periods were associated with a 33% to 38% lower risk of a registered minor offense than low-adherence periods, with no comparable association for antidepressants, used as a comparison (Rosenau et al., 2024). A Swedish study of 148,581 people newly diagnosed with ADHD emulated a randomized trial, comparing those who started medication within three months with those who did not; over two years, the rate of a first conviction was 13% lower in the medication group (65.1 vs. 76.1 per 1,000 person-years), and the rate of recurrent convictions 25% lower (Zhang et al., 2025). In U.S. insurance claims for nearly 3 million patients, substance-related emergency visits were less likely during medicated months (Quinn et al., 2017).

A Norwegian study used the fact that clinics differ in how readily they prescribe. Among 5,624 patients aged 10 to 18, medication reduced violence-related and public-order charges over four years for patients whose treatment depended on their clinic’s preference, with no evidence of an effect on drug, traffic, sexual, or property charges; the authors linked the effect to impulsive, reactive crime and found none for crimes requiring intent and planning (Widding-Havneraas et al., 2024).

Lichtenstein et al. (2012) and Zhang et al. (2025) found larger reductions in criminality among women than men (in Zhang et al., incidence rate ratios 0.81 and 0.90); Quinn et al. (2017) found similar reductions in substance-related events for both sexes, and the Dutch reductions held for each sex (Rosenau et al., 2024). These group comparisons say nothing about any individual woman or man.

What Within-Individual Designs Can and Cannot Show

The within-individual design compares a person with himself or herself, removing confounding by anything constant over the follow-up, such as genes and childhood environment (Lichtenstein et al., 2012). It does not remove factors that change with medication, as when a person starts medication on finding work and stops on starting drug use. Lichtenstein et al. found the association whether people moved onto or off medication, but no such analysis excludes every time-varying explanation. A review of 40 pharmacoepidemiology studies concluded that criminality findings needed replication, long-term effects were less clear, and time-varying confounding remained a central limitation (Chang et al., 2019).

Convictions and charges reflect detection as well as conduct, and dispensed prescriptions do not show that pills were taken. The within-individual estimate comes only from people who started or stopped medication, who may differ from those who never did. Trial emulation addresses differences measured at the start, not unmeasured ones, and the Norwegian design estimates an effect only for patients whose treatment depended on clinic preference (Widding-Havneraas et al., 2024; Zhang et al., 2025). The effects were largely concurrent, not a lasting change after medication stops. In the long-term follow-up of a major U.S. childhood treatment trial, stimulant treatment neither raised nor lowered later delinquency and substance-use risk (Barkley, 2015). Taken together, the findings are consistent with a real but modest, short-term effect on general offending, most evident for impulsive and reactive offenses, in people who take the medication; they neither establish nor exclude an effect on sexual offending.

Evidence on Sexual Offending Specifically

The evidence on sexual offending is thin. Sexual convictions were rare: 0.7% of the men and almost none of the women in the Swedish sample had one during follow-up. That study grouped sexual with violent crimes, and neither it nor the Swedish trial emulation reported a separate sexual-crime estimate (Lichtenstein et al., 2012; Zhang et al., 2025). The Norwegian quasi-experiment, the only study located that estimated an effect on sexual charges, found no evidence of one; its abstract gives neither the number of sexual charges nor the precision of the estimate, so a small effect cannot be ruled out (Widding-Havneraas et al., 2024). The lack of evidence neither shows that medication has no effect on sexual offending nor that it has one.

The only treatment study located that examined stimulant medication and sexual behavior is an open case series of 26 men with paraphilias or paraphilia-related disorders already taking a selective serotonin reuptake inhibitor; adding sustained-release methylphenidate was associated with further reductions in total sexual outlet and time spent in the target behaviors, and in residual ADHD and depressive symptoms (Kafka & Hennen, 2000). The study had no control group, mixed paraphilic with nonparaphilic hypersexual behavior, did not measure offending, and is more than 25 years old. It supports a clinical hypothesis, not a conclusion about sexual reoffending.

No study located has tested whether ADHD medication changes sexual interest in children, use of child sexual abuse material, or sexual recidivism. If impulsivity or disinhibition contributed to an offense, treating them may plausibly help; offenses involving sustained planning, grooming, or a stable sexual interest may be less responsive, a hypothesis consistent with the Norwegian pattern but not tested for sexual offending (Widding-Havneraas et al., 2024). Whether ADHD played any role in a specific offense is a question for the individual evaluation.

Psychosocial Treatment

A meta-analysis of 32 studies of cognitive-behavioral therapy (CBT) for adults with ADHD found small-to-medium effects compared with control conditions on symptoms and functioning, smaller effects against active treatments, and wide variation across studies; medication status did not moderate improvement (Knouse et al., 2017). In an Icelandic randomized trial of 95 adults already taking medication, 15 sessions of the R&R2ADHD program reduced clinician-rated and self-rated ADHD symptoms more than treatment as usual, with gains maintained at three months (Young et al., 2015). It measured symptoms, not offending, and did not involve people convicted of sexual offenses. A United Kingdom expert consensus recommends combining medication with psychological treatment across prison, probation, and community care (Young et al., 2018), a matter of expert judgment rather than trial results.

ADHD Within Sex-Offender Treatment Programs

Under the risk-need-responsivity model that organizes most sex-offender treatment, ADHD is a responsivity consideration: delivery should fit the person’s abilities. A text on online sexual offending notes that ADHD is more common among clients with hypersexuality or paraphilic disorders and may affect participation, and that the risk-need-responsivity framework has not yet been tested specifically for online offending (Seto, 2025).

ADHD may affect attendance, homework, attention in group sessions, and the use of skills under stress, which can be misread as low motivation or denial; they can also reflect low motivation, and the evaluation has to distinguish the two. No study located has compared sex-offender treatment outcomes for participants with and without ADHD, or tested whether treating ADHD improves completion or sexual recidivism. Adapting treatment for ADHD is a reasonable clinical judgment, not an evidence-based intervention for sexual reoffending, and it does not replace targets such as sexual self-regulation and offense-supportive attitudes.

Medication in Custody: Trials, Diversion, and Misuse

About one in four incarcerated adults is diagnosed positive for ADHD by clinical interview (25.5% pooled across 42 studies; Young, Moss, et al., 2015); this is a base rate for incarcerated people and does not establish a diagnosis in an individual. Two placebo-controlled trials in prisons conflict. In a Swedish high-security prison, 30 men with ADHD and co-occurring disorders were randomized to osmotic-release methylphenidate or placebo for five weeks, then treated openly to 52 weeks; symptoms improved with a very large effect (Ginsberg & Lindefors, 2012). At three-year follow-up, 40% of 20 respondents self-reported reoffending, which the authors considered lower than expected, in a small sample uncontrolled after five weeks (Ginsberg et al., 2015). A larger trial of men aged 16 to 25 in United Kingdom prisons found no difference between methylphenidate and placebo on symptoms after eight weeks (responders 48.3% vs. 47.9%) or on 13 secondary outcomes, including staff ratings of aggression; the authors did not support routine use of that medication in this population and called for research on higher doses and adherence (Asherson et al., 2023). Both trials included only men.

Misuse and diversion are the main reason ADHD medication remains controversial in prisons, according to a narrative review that found only seven relevant studies (Grimley & Bartels, 2024). Outside custody, a systematic review found that 16% to 29% of students with stimulant prescriptions had been asked to give, sell, or trade them (Wilens et al., 2008), and a 2025 meta-analysis of 12 surveys of people prescribed stimulants estimated past-year misuse at 22.6% and diversion at 18.2% (Forrest et al., 2025). These were community and student samples; the rate in jails and prisons is unknown.

The ADHD handbook recommends a substance-use history and a diversion plan before prescribing, notes that nonstimulants such as atomoxetine have low abuse potential, and cautions that people may feign ADHD to obtain stimulants or for gain in legal settings, including sentencing (Barkley, 2015). A defendant who sought stimulants without a documented diagnosis raises one question; a documented diagnosis left untreated in custody raises another.

Adherence is the practical limit on any medication-based plan. Among more than 1.2 million new users in nine jurisdictions, only 39% of young adults aged 18 to 24 and 48% of adults 25 and older remained on treatment one year after starting (Brikell et al., 2024). Because the register benefits were concentrated in medicated periods, a plan assuming continuous treatment should anticipate interruption.

Limits of the Evidence

The strongest studies are large registers measuring convictions, charges, or emergency visits, with medication defined by dispensed prescriptions. Within-individual comparisons remove stable confounders but not changing circumstances; trial emulation and provider-preference designs address some confounding; and the custody trials are small, short, male-only, and inconsistent. Sexual offending has been examined separately in one quasi-experimental study, which found no evidence of an effect, and in one small, uncontrolled case series. No study located has examined medication and sexual recidivism in people convicted of sexual offenses. Most cohorts were young and Scandinavian. Lower average rates do not show that a particular defendant’s offense was caused by untreated ADHD or that his risk will fall if he is treated.

Questions to Ask About This Research

When the 32% figure (Lichtenstein et al., 2012) is offered, ask what was counted (any conviction, in Sweden, 2006 to 2009), what was compared (the same people on and off medication), and whether sexual offenses were analyzed separately (they were not; they were grouped with violent crime). When a register finding is offered to predict that a medicated defendant will not reoffend, ask whether the effect was concurrent or lasting, whether it concerned impulsive or planned crime, and whether the defendant has taken medication consistently before. When it is offered to dismiss treatment, ask whether general-crime reductions were considered. When custody treatment is debated, ask which trial is cited, the positive Swedish trial (Ginsberg & Lindefors, 2012) or the null British one (Asherson et al., 2023). When CBT is recommended, ask whether the outcomes were symptoms or offending. These questions are explained in “Reading Research Claims: A Guide for Attorneys” on this site.

ADHD Treatment and the Law

Federal and Military Standards

Expert testimony about ADHD treatment is subject to Federal Rule of Evidence 702, amended December 1, 2023, to require the proponent to show by a preponderance that the opinion rests on sufficient facts and reliable methods reliably applied (Daubert v. Merrell Dow Pharmaceuticals, Inc., 1993); Kumho Tire Co. v. Carmichael (1999) extends that gatekeeping to all expert testimony. An opinion that medication will reduce a defendant’s sexual-offense risk extrapolates from general-crime outcomes and should say so. At sentencing, 18 U.S.C. § 3553(a)(2)(D) directs the court to consider the need to provide medical care or other correctional treatment in the most effective manner. Amendment 836 (effective Nov. 1, 2025) moved most departures, including the Chapter 5H specific-offender-characteristic policy statements, to Appendix B; the Commission described the change as outcome neutral, and the same facts may be considered for a variance under 18 U.S.C. § 3553(a).

A court may require a probationer to undergo medical, psychiatric, or psychological treatment (18 U.S.C. § 3563(b)(9)); supervised-release conditions must be reasonably related to the sentencing factors and involve no greater deprivation of liberty than reasonably necessary (18 U.S.C. § 3583(d)). The Ninth Circuit, which includes Arizona, has held that a condition requiring antipsychotic medication may be imposed only on medically grounded, on-the-record findings that it is necessary and involves no greater deprivation of liberty than reasonably necessary (United States v. Williams, 2004), and later extended that requirement to any treatment or medication implicating a particularly significant liberty interest (United States v. Cope, 2008). No published appellate decision was located on whether ADHD medication in particular implicates that interest. For convicted prisoners, deliberate indifference to serious medical needs violates the Eighth Amendment, but the choice of treatment is generally a matter of medical judgment (Estelle v. Gamble, 1976).

Hypothetical Example: Consider a hypothetical 31-year-old man convicted of receiving child sexual abuse material, with school records documenting ADHD and stimulant treatment from age 8 until he stopped at 19. A presentence evaluation recommends resuming ADHD treatment and adapting group treatment, and probation proposes a condition requiring him to take all medication as prescribed. The research supports treating ADHD within a supervision plan and suggests untreated symptoms could interfere with treatment. It does not show that medication reduces use of such material or sexual recidivism, and his history of stopping fits a common pattern in young adulthood, though group data cannot say whether he will stop again. In the Ninth Circuit, a blanket medication requirement may call for specific findings; a condition requiring treatment participation and prescriber follow-up, with documented adherence, stays closer to what the evidence supports.

In courts-martial, Military Rule of Evidence 702 governs; the 2023 federal amendment took effect in the military rule in 2025 (Joint Service Committee on Military Justice, 2025), and practitioners should confirm current text. Under R.C.M. 1107(c) (2024 Manual for Courts-Martial; check later amendments), conditions of a suspended sentence must be specified in writing and served on the probationer, so treatment conditions should be stated precisely.

Arizona

Arizona Rule of Evidence 702 was amended, effective January 1, 2024, to conform to the federal amendment (Order R-23-0004). Under A.R.S. § 13-901(B), as amended in 2026 (Laws 2026, ch. 186), unless otherwise required by law, probation conditions must be reasonably necessary, individually determined, and narrowly tailored to a law-abiding life, public safety, and rehabilitation; they are to be informed by criminogenic risk and needs from a validated risk assessment tool and by any presentence report, and a special condition must be supported by the record. A condition requiring ADHD treatment or a particular medication therefore needs support in the individual evaluation, not the diagnosis alone. Statutory conditions for sex offenses and lifetime probation should be checked separately, as should whether the amendment applies to an offense committed before its effective date; the act as read contains no applicability clause. Under A.R.S. § 13-701(E), the court considers as mitigating any factor relevant to character or background, which may include treatment history (see “Culpability and Sentencing Mitigation”).

Special Issues in Legal Practice

The principles described above apply with equal force to every party in a legal proceeding. The science operates the same way regardless of who is asking the questions, and the research summarized here does not by itself favor either side. What differs between the parties is not the science but the vantage point — the particular places where these issues tend to surface, and the particular errors each party is best positioned to guard against. The two summaries below identify those recurring issues. They are offered for orientation, not as litigation strategy; in every case the controlling question is what the evidence in that case will, and will not, support, and the expert’s role is to inform the trier of fact rather than to advocate for either side.

Special Issues for Prosecutors

The research supports treating ADHD as one part of a structured supervision plan, with treatment participation, prescriber follow-up, and adherence documented. It supports asking whether a claimed diagnosis predates the charges, whether the defendant took medication consistently, and whether he has misused or diverted stimulants, questions the clinical literature treats as part of responsible prescribing. The measured benefits concern general offending, mostly impulsive and reactive crime, and no study shows that medication reduces sexual reoffending or use of child sexual abuse material. Where an offense involved planning, grooming, or a sustained pattern, the register findings may be of limited relevance.

The research also counsels caution. The register studies are large and consistent across several countries with a modest, short-term association between medicated periods and lower general-crime rates; confounding that changes over time cannot be excluded and sexual offenses were not isolated, so ADHD treatment is relevant to risk management, but the studies do not show that medication lowers a defendant’s risk, and calling it irrelevant or presenting it as proven to reduce offending each goes beyond them. Untreated ADHD can interfere with participation in sex-offender treatment, so a defendant who did not complete treatment was not necessarily unwilling. Clinical guidance addresses diversion through screening, formulation, and nonstimulant options rather than withholding treatment. In the Ninth Circuit, a broadly worded condition compelling medication may require specific, medically grounded findings.

Special Issues for Defense

The research supports presenting ADHD treatment as part of a concrete plan: a documented diagnosis, a prescriber, a medication history, skills-based therapy, and adaptations that let the defendant use sex-offender treatment. Register studies found lower conviction and charge rates during medicated periods, and CBT improves adult ADHD symptoms, so sustained engagement in treatment is a legitimate responsivity and mitigation consideration. Pharmacy and school records, and conditions requiring treatment participation and medical follow-up rather than unspecified medication, fit the evidence.

The research also counsels caution. No study shows that ADHD medication reduces sexual offending, and the one quasi-experimental study that examined sexual charges found no evidence of an effect. Register benefits were largely concurrent with medication, and many young adults stop within a year, so a claim that treatment will prevent reoffending outruns the evidence and may be tested against the defendant’s adherence history. A diagnosis first made after arrest, combined with a request for stimulants, invites scrutiny for feigning and diversion. Treatability is one consideration; it does not address harm to victims or the other purposes of sentencing.

This paper is for educational purposes only and is not legal advice. The author is a psychologist, not an attorney; summaries of law are general and must be verified against current authority or with a licensed attorney.

References

Asherson, P. J., Johansson, L., Holland, R., Bedding, M., Forrester, A., Giannulli, L., Ginsberg, Y., Howitt, S., Kretzschmar, I., Lawrie, S. M., Marsh, C., Kelly, C., Mansfield, M., McCafferty, C., Khan, K., Müller-Sedgwick, U., Strang, J., Williamson, G., Wilson, L., . . . Thomson, L. D. G. (2023). Randomised controlled trial of the short-term effects of osmotic-release oral system methylphenidate on symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder: CIAO-II study. The British Journal of Psychiatry, 222(1), 7–17. https://doi.org/10.1192/bjp.2022.77

Barkley, R. A. (Ed.). (2015). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (4th ed.). Guilford Press.

Brikell, I., Yao, H., Li, L., Astrup, A., Gao, L., Gillies, M. B., Xie, T., Zhang-James, Y., Dalsgaard, S., Engeland, A., Faraone, S. V., Haavik, J., Hartman, C., Ip, P., Jakobsdóttir Smári, U., Larsson, H., Man, K. K., de Oliveira Costa, J., Pearson, S. A., . . . Chang, Z. (2024). ADHD medication discontinuation and persistence across the lifespan: A retrospective observational study using population-based databases. The Lancet Psychiatry, 11(1), 16–26. https://doi.org/10.1016/S2215-0366(23)00332-2

Chang, Z., Ghirardi, L., Quinn, P. D., Asherson, P., D’Onofrio, B. M., & Larsson, H. (2019). Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: A qualitative review of pharmacoepidemiology studies using linked prescription databases. Biological Psychiatry, 86(5), 335–343. https://doi.org/10.1016/j.biopsych.2019.04.009

Forrest, J., Chen, W., & Jagadheesan, K. (2025). Misuse and diversion of stimulant medications prescribed for the treatment of ADHD: A systematic review. Frontiers in Psychiatry, 16, Article 1612785. https://doi.org/10.3389/fpsyt.2025.1612785

Ginsberg, Y., Långström, N., Larsson, H., & Lindefors, N. (2015). Long-term treatment outcome in adult male prisoners with attention-deficit/hyperactivity disorder: Three-year naturalistic follow-up of a 52-week methylphenidate trial. Journal of Clinical Psychopharmacology, 35(5), 535–543. https://doi.org/10.1097/JCP.0000000000000395

Ginsberg, Y., & Lindefors, N. (2012). Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: Randomised double-blind placebo-controlled trial with open-label extension. The British Journal of Psychiatry, 200(1), 68–73. https://doi.org/10.1192/bjp.bp.111.092940

Grimley, A., & Bartels, L. (2024). The need for speed? Exploring the risks and benefits of pharmacological treatment for adult ADHD in prisons. Psychiatry, Psychology and Law, 31(6), 1131–1151. https://doi.org/10.1080/13218719.2023.2260861

Joint Service Committee on Military Justice. (2025). Amendments to the Military Rules of Evidence since 1984 (G. E. Maggs, Ed.; 2025 ed.). https://jsc.defense.gov/Portals/99/MRE%20Amendments%202025.pdf

Kafka, M. P., & Hennen, J. (2000). Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: A case series. The Journal of Clinical Psychiatry, 61(9), 664–670. https://doi.org/10.4088/JCP.v61n0912

Knouse, L. E., Teller, J., & Brooks, M. A. (2017). Meta-analysis of cognitive–behavioral treatments for adult ADHD. Journal of Consulting and Clinical Psychology, 85(7), 737–750. https://doi.org/10.1037/ccp0000216

Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2012). Medication for attention deficit–hyperactivity disorder and criminality. New England Journal of Medicine, 367(21), 2006–2014. https://doi.org/10.1056/NEJMoa1203241

Mohr-Jensen, C., Müller Bisgaard, C., Boldsen, S. K., & Steinhausen, H.-C. (2019). Attention-deficit/hyperactivity disorder in childhood and adolescence and the risk of crime in young adulthood in a Danish nationwide study. Journal of the American Academy of Child & Adolescent Psychiatry, 58(4), 443–452. https://doi.org/10.1016/j.jaac.2018.11.016

Quinn, P. D., Chang, Z., Hur, K., Gibbons, R. D., Lahey, B. B., Rickert, M. E., Sjölander, A., Lichtenstein, P., Larsson, H., & D’Onofrio, B. M. (2017). ADHD medication and substance-related problems. American Journal of Psychiatry, 174(9), 877–885. https://doi.org/10.1176/appi.ajp.2017.16060686

Rosenau, P. T., Dietrich, A., van den Hoofdakker, B. J., & Hoekstra, P. J. (2024). ADHD medication adherence reduces risk of committing minor offenses in adolescents. Journal of Child Psychology and Psychiatry, 65(11), 1478–1485. https://doi.org/10.1111/jcpp.13997

Seto, M. C. (2025). Online sexual offending: Theory, practice, and policy (2nd ed.). American Psychological Association. https://doi.org/10.1037/0000428-000

Widding-Havneraas, T., Zachrisson, H. D., Markussen, S., Elwert, F., Lyhmann, I., Chaulagain, A., Bjelland, I., Halmøy, A., Rypdal, K., & Mykletun, A. (2024). Effect of pharmacological treatment of attention-deficit/hyperactivity disorder on criminality. Journal of the American Academy of Child & Adolescent Psychiatry, 63(4), 433–442. https://doi.org/10.1016/j.jaac.2023.05.025

Wilens, T. E., Adler, L. A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R., Utzinger, L., & Fusillo, S. (2008). Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child & Adolescent Psychiatry, 47(1), 21–31. https://doi.org/10.1097/chi.0b013e31815a56f1

Young, S., Gudjonsson, G., Chitsabesan, P., Colley, B., Farrag, E., Forrester, A., Hollingdale, J., Kim, K., Lewis, A., Maginn, S., Mason, P., Ryan, S., Smith, J., Woodhouse, E., & Asherson, P. (2018). Identification and treatment of offenders with attention-deficit/hyperactivity disorder in the prison population: A practical approach based upon expert consensus. BMC Psychiatry, 18, Article 281. https://doi.org/10.1186/s12888-018-1858-9

Young, S., Khondoker, M., Emilsson, B., Sigurdsson, J. F., Philipp-Wiegmann, F., Baldursson, G., Olafsdottir, H., & Gudjonsson, G. (2015). Cognitive–behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: A randomized controlled trial using multi-level analysis. Psychological Medicine, 45(13), 2793–2804. https://doi.org/10.1017/S0033291715000756

Young, S., Moss, D., Sedgwick, O., Fridman, M., & Hodgkins, P. (2015). A meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations. Psychological Medicine, 45(2), 247–258. https://doi.org/10.1017/S0033291714000762

Zhang, L., Zhu, N., Sjölander, A., Nourredine, M., Li, L., Garcia-Argibay, M., Kuja-Halkola, R., Brikell, I., Lichtenstein, P., D’Onofrio, B. M., Larsson, H., Cortese, S., & Chang, Z. (2025). ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: Emulation of target trials. BMJ, 390, Article e083658. https://doi.org/10.1136/bmj-2024-083658

Legal Authorities

Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993).

Estelle v. Gamble, 429 U.S. 97 (1976).

Kumho Tire Co. v. Carmichael, 526 U.S. 137 (1999).

United States v. Cope, 527 F.3d 944 (9th Cir. 2008).

United States v. Williams, 356 F.3d 1045 (9th Cir. 2004).

U.S. Const. amend. VIII.

18 U.S.C. § 3553(a).

18 U.S.C. § 3563(b)(9).

18 U.S.C. § 3583(d).

Ariz. Rev. Stat. Ann. §§ 13-701(E), 13-901 (as amended by 2026 Ariz. Sess. Laws ch. 186 (S.B. 1662)).

Fed. R. Evid. 702.

Ariz. R. Evid. 702.

Mil. R. Evid. 702.

Rule for Courts-Martial 1107(c).

U.S. Sentencing Guidelines Manual app. B (U.S. Sentencing Comm’n 2025) (former Chapter 5H policy statements).

Related topic papers: ADHD and Sexual Offending: What the Research Shows · Diagnosing ADHD in Adult Defendants: Records, Rating Scales, and Feigning · ADHD in Police Interviews, Court, and Sentencing · Treatment for Adolescents Who Sexually Offend · Plea Comprehension, Probation Conditions, and Supervision for Defendants With Cognitive Impairments · Jail, Prison, and Vulnerability: Special Populations in Custody

Related topics from Arizona Forensic Services: Psychosexual Risk Evaluations · Online Sex Offense · Courts-Martial